Treatments that reduce suffering and incorporate patient values aren’t common in kidney disease care. That’s changing
Demand for healthy kidneys has long outstripped supply. But better testing and treatment are expanding the donor pool
Minority patients are diagnosed later, stay on dialysis longer and are added to transplant lists less quickly. Why?
Nurse Kristen Choi says health care providers need to better educate patients about possible side effects from the COVID-19 vaccine. Christopher Intagliata reports.
Joint ventures between nephrologists and dialysis centers have expanded treatment. Critics ask: At what cost?
Kidney disease affects millions of Americans, but corporate capture of dialysis, along with disparities in treatment and transplant access, mean that not everyone's journey is the same...
A new California law aims to curb what sponsors say is profiteering by dialysis centers. But are there any easy answers?
Even with vaccines on the way, treatments are needed to prevent the disease from getting worse—and to be ready for COVID-25, COVID-37, and so on
The FDA issued the emergency use authorization for the vaccine late on Friday. And immunizations of health care workers and long-term care facility residents could begin within days...
Stephen Hahn describes how the agency will evaluate vaccines for emergency authorization
Anyone who’s been hospitalized has probably asked this question—and probably never found out
In the U.S., health workers come first. But for other groups, scientists and policy makers are weighing a mix of disease risks, logistics and ethics
A vaccine logistics expert explains how millions of frozen vials will be widely distributed
Mathematicians model pandemic scenarios by plugging thorny ethical and logistical issues into calculations
Paratek Pharmaceuticals made a life-saving drug and got it approved. So why is the company’s long-term survival still in question?
They could ultimately be used to find diseases the way blood tests do now—but cheaper and more easily
Much of the pioneering work on mRNA vaccines was done with government money, though drugmakers could walk away with big profits
Preliminary data show that the immunization is 94 percent effective and seems to prevent severe infections
There have been mixed results as researchers try to stop a disease they are still trying to understand
Bedside imaging holds vast potential as a diagnostic tool, especially during the pandemic